

# Past, Present & Future of the Total-Body PET: Clinical Perspective


Axel Rominger

Department of Nuclear Medicine, University of Bern, Switzerland



**BIOGRAPH Vision**  
Quadra

# PET Technology Advancements



Vandenberghe et al 2020 EJNMMI Physics




## Total-body PET/CT or LAFOV PET/CT? Axial field-of-view clinical classification

Clemens Mingels<sup>1,2</sup> · Federico Caobelli<sup>1</sup> · Abass Alavi<sup>3</sup> · Christos Sachpekidis<sup>4</sup> · Meiyun Wang<sup>5</sup> · Hande Nalbant<sup>2</sup> · Austin R. Pantel<sup>3</sup> · Hongcheng Shi<sup>6</sup> · Axel Rominger<sup>1</sup> · Lorenzo Nardo<sup>2</sup>


Received: 9 November 2023 / Accepted: 17 November 2023  
© Springer-Verlag GmbH Germany, part of Springer Nature 2023

SAFOV < 100 cm  
LAFOV > 100 cm



# PET Technology Advancements

|  |                                  |  |   |   |
|--|----------------------------------|--|---|---|
| Early PET (1970s):<br>NaI<br>PMT<br>Si | 1980-1990s:<br>BGO scintillators | 2000-2010s:<br>LSO scintillators<br>PMT<br>Multi ring<br>Axial FoV ~ 20 cm | 2010-2020s:<br>LSO scintillators<br>SiPM<br>Multi ring<br>Axial FoV ~ 25 cm | >2020:<br>LSO scintillators<br>SiPM<br>Multi ring<br>Axial FoV > 100 cm |
|--|----------------------------------|--|---|---|



>>60min


~15min

Analog PET

Digital PET

**SAFOV-PET**


**LAFOV-PET**



# Overview commercial digital PET systems



GE  
Discovery MI  
Omni Legend (- - -> LAFOV)



Siemens Biograph Vision 450/600  
Biograph Vision X  
Biograph Vision Quadra (LAFOV)




United  
uMI  
Explorer (LAFOV)  
Panorama  
Panorama GS (LAFOV)

# Illustration of the Performance over the last 10 years



Acq  
time  
1 min


Analog SAFOV




Digital SAFOV




LAFOV



Acq  
time  
2 min



# Body coverage



All major organs are included!




# Flat Panel PET

## Walk-through flat panel total-body PET: a patient-centered design for high throughput imaging at lower cost using DOI-capable high-resolution monolithic detectors

Stefaan Vandenberghe<sup>1</sup> · Florence M. Muller<sup>1</sup> · Nadia Withofs<sup>2</sup> · Meysam Dadgar<sup>1</sup> · Jens Maebe<sup>1</sup> · Boris Vervenne<sup>1</sup> · Maya Abi Akli<sup>1</sup> · Song Xue<sup>3</sup> · Kuangyu Shi<sup>2</sup> · Giancarlo Sportelli<sup>4</sup> · Nicola Belcari<sup>4</sup> · Roland Hustinx<sup>2</sup> · Christian Vanhove<sup>1</sup> · Joel S. Karp<sup>5</sup>

Received: 23 May 2023 / Accepted: 7 July 2023 / Published online: 19 July 2023  
© The Author(s) 2023



**Table 3** PET component cost analysis (including the scintillator, SiPM, and electronics) comparing a standard PET-CT (SAFOV), a conventional 106 cm TB-PET-CT (LAFOV), and the proposed walk-through TB-PET system. Only the costs of the PET part are considered. The cost of the electronics was not calculated as it is harder as

it is harder to estimate and depends strongly on the chosen detector concept and the amount of channels. Based on our first estimates the electronics of our design will be lower cost than for a full pixelated LAFOV scanner

|  | Scintillator   | SiPM   | PET component cost |
|--|--|--|--------------------|
| Component cost   | Li(Y)SO: 30 Euro/cc<br>BGO: 10 Euro/cc   | 1000 Euro/module<br>One module: 5 × 5 cm surface (8 × 8 array of 6 × 6 mm SiPM)  |                    |
| SAFOV (85 cm diameter, 20-mm-thick LSO, 26-cm axial FOV)                     | $\pi \times 85 \text{ cm} \times 2 \text{ cm} \times 26 \text{ cm} \times 30 \text{ Euro/cc}$<br>= 416 kEuro           | $\pi \times 85 \text{ cm} \times 26 \text{ cm} / (5 \text{ cm} \times 5 \text{ cm}) \times 1000 \text{ Euro}$<br>= 278 kEuro           | 694 kEuro          |
| LAFOV (85 cm diameter, 20 mm thick LSO, 4 × 106 cm axial FOV)                | $\pi \times 85 \text{ cm} \times 2 \text{ cm} \times 26 \text{ cm} \times 4 \times 30 \text{ Euro/cc}$<br>= 1666 kEuro | $\pi \times 85 \text{ cm} \times 4 \times 26 \text{ cm} / (5 \text{ cm} \times 5 \text{ cm}) \times 1000 \text{ Euro}$<br>= 1112 kEuro | 2776 kEuro         |
| WT-TB-PET (2 panels of 70-cm width each, 106-cm axial FOV, 16-mm-thick BGO)  | $2 \times 70 \text{ cm} \times 106 \text{ cm} \times 1.6 \text{ cm} \times 10 \text{ Euro/cc}$<br>= 237 kEuro          | $2 \times 70 \text{ cm} \times 106 \text{ cm} / (5 \text{ cm} \times 5 \text{ cm}) \times 1000 \text{ Euro}$<br>= 593 kEuro            | 830 kEuro          |
| WT-TB-PET (2 panels of 70 cm width each, 106 cm axial FOV, 16-mm-thick LYSO) | $2 \times 70 \text{ cm} \times 106 \text{ cm} \times 1.6 \text{ cm} \times 30 \text{ Euro/cc}$<br>= 711 kEuro          | $2 \times 70 \text{ cm} \times 106 \text{ cm} / (5 \text{ cm} \times 5 \text{ cm}) \times 1000 \text{ Euro}$<br>= 593 kEuro            | 1304 kEuro         |

Advantages:  
Low-cost  
Fast throughput  
High spatial resolution



# J-PET



## ORIGINAL RESEARCH

## Open Access



# Efficiency determination of J-PET: first plastic scintillators-based PET scanner

S. Sharma<sup>1,2,7\*</sup>, J. Baran<sup>1,2,7</sup>, N. Chug<sup>1,2,7</sup>, C. Curceanu<sup>3</sup>, E. Czerwiński<sup>1,2,7</sup>, M. Dadgar<sup>1,2,7</sup>, K. Dulski<sup>1,2,7</sup>, K. Eliyan<sup>1,2,7</sup>, A. Gajos<sup>1,2,7</sup>, N. Gupta-Sharma<sup>1,2</sup>, B. C. Hiesmayr<sup>4</sup>, K. Kacprzak<sup>1,2,7</sup>, Ł. Kapłon<sup>1,2,7</sup>, K. Klimaszewski<sup>5</sup>, P. Konieczka<sup>5</sup>, G. Korcyl<sup>1,2</sup>, T. Kozik<sup>1</sup>, W. Krzemier<sup>6</sup>, D. Kumar<sup>1,2,7</sup>, Sz. Niedźwiecki<sup>1,2,7</sup>, D. Panek<sup>1,2,7</sup>, S. Parzych<sup>1,2,7</sup>, E. Perez del Rio<sup>1,2,7</sup>, L. Raczyński<sup>5</sup>, Shivani Choudhary<sup>1,2,7</sup>, R. Y. Shopa<sup>5</sup>, M. Skurzok<sup>1,2,7</sup>, E. Ł. Stępień<sup>1,2,7</sup>, F. Tayefi<sup>1,2,7</sup>, K. Tayefi<sup>1,2,7</sup>, W. Wiślicki<sup>6</sup> and P. Moskal<sup>1,2,7</sup>



# Perspectives



analog  
PET/CT




digital  
PET/CT



Total body  
PET/CT


# Total-Body PET/CT Imaging - Perspectives



High-sensitivity


Fast acquisition

Low radiation burden



Quantitative accuracy

Whole-body parametric imaging




Multi-tracer studies

Drug discovery


High temporal resolution

Organ interaction, e.g. brain-gut, brain-spine, brain-heart

Late low-dose Imaging  
→ immune cells




# Total-Body PET/CT Imaging - Perspectives



High-sensitivity


Fast acquisition

Low radiation burden



Quantitative accuracy

Whole-body parametric imaging




Multi-tracer studies

Organ interaction, e.g. brain-gut, brain-spine, brain-heart

Late low-dose Imaging  
→ immune cells

Drug discovery

High temporal resolution



# Which is the killer application?




**FLEXIBILITY**



# Top diagnostic quality



**Radiation  
exposure**




MBq


time

**Throughput /  
patient comfort**

# Image Impressions



10 min



2 min




440x440 matrix  
3MBq/kg FDG

PET MIP




**Vision Quadra**  
120 min. p.i.  
180 sec  
440x440 matrix




**Vision Quadra**  
120 min. p.i.  
120 sec  
440x440 matrix



**Vision Quadra**  
120 min. p.i.  
90 sec  
440x440 matrix




**Vision Quadra**  
120 min. p.i.  
60 sec  
440x440 matrix



**Vision Quadra**  
120 min. p.i.  
30 sec  
440x440 matrix






**Vision Quadra**  
120 min. p.i.  
2 min  
440x440 matrix








10 min



2min



PSA 24.8 ng/ml  
238 MBq **F18-PSMA1007**  
82 kg / 183 cm



NET G1  
163 MBq **Ga68-DOTATOC** 10 min  
99 kg / 180 cm

4 min


2 min

European Journal of Nuclear Medicine and Molecular Imaging  
<https://doi.org/10.1007/s00259-021-05282-7>


ORIGINAL ARTICLE



# Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT

Ian Alberts<sup>1</sup> • Jan-Niklas Hünermund<sup>1</sup> • George Prenosil<sup>1</sup> • Clemens Mingels<sup>1</sup> • Karl Peter Bohn<sup>1</sup> • Marco Viscione<sup>1</sup> • Hasan Sari<sup>1,2</sup> • Bernd Vollnberg<sup>1</sup> • Kuangyu Shi<sup>1</sup> • Ali Afshar-Oromieh<sup>1</sup> • Axel Rominger<sup>1</sup> 

## SNR in LAFOV compared to SAFOV








2 min in LAFOV correspond to 16 min in SAFOV

# Business Cases are Possible


Triple negative Mamma-Ca, Staging. Adipositas permagna.  
397 MBq F-18-FDG; 6 min acq.

**Non-optimal conditions**





## Non-optimal conditions



87y male patient with  
adenocarcinoma AEG,  
BG: 12.3 mmol/l, 1.64m 85kg  
BMI 32kg/m<sup>2</sup>  
uptake time: 60min  
6min acquisition

Mingels et al. SNM 2023







## FDG imaging with long-axial field-of-view PET/CT in patients with high blood glucose—a matched pair analysis

Clemens Mingels<sup>1</sup> · Luis Weissenrieder<sup>1</sup> · Konstantinos Zeimpekis<sup>1</sup> · Hasan Sari<sup>1,2</sup> · Lorenzo Nardo<sup>3</sup> · Federico Caobelli<sup>1</sup> · Ian Alberts<sup>4</sup> · Axel Rominger<sup>1</sup> · Thomas Pyka<sup>1</sup>


**C Tumor Uptake**  
(BG 8–11 mmol/l)




**D Image Quality**  
(BG 8–11 mmol/l)






**E Tumor Uptake**  
(BG >11 mmol/l)



If BG is elevated a longer acq. on a LAFOV system can compensate the altered biodistribution



**Background Noise**  
(Liver)




OPEN




Original article

## Investigating the influence of long-axial versus short-axial field of view PET/CT on stage migration in lymphoma and non-small cell lung cancer

Ian Alberts<sup>a</sup>, Sigrid Seibel<sup>a</sup>, Song Xue<sup>a</sup>, Marco Viscione<sup>a</sup>, Clemens Mingels<sup>a</sup>, Hasan Sari<sup>a,b</sup>, Ali Afshar-Oromieh<sup>a</sup>, Andreas Limacher<sup>c</sup> and Axel Rominger<sup>a</sup>



- LAFOV system did not lead to upstaging in lymphoma nor NSCLC compared to a digital SAFOV system.
- Diagnostic accuracy was comparable between the two systems in NSCLC despite shorter acquisition times for LAFOV.



# Expanding the Horizon

## INDICATIONS



- diagnosis of tumor
- tumor metastasis
- rare diseases
- immunological disorders
- cardiovascular
- neurological



## IMAGING


- ultrafast
- low-dose
- delayed
- dual tracer
- dynamic

post adenocarcinoma upper lobe L  
190 MBq F-18-FDG



4 min acquisition during regular breathing

post adenocarcinoma upper lobe L  
190 MBq F-18-FDG



10 sec DIBH

# Scanning with Low Dose Activity

## offers the possibility of...

- ALARA principle
- Multiple follow-up PET scans, also short-term FU
- Administration of **different radiotracers** for further characterization of tumors → personalized approaches
- Save cost for radiopharmaceuticals
- Bring **new radiopharmaceuticals** into humans
- Find new indications (non-oncological, early detection, screening)

# Drugmakers bet billions that targeted radiation could become the next cancer breakthrough

PUBLISHED MON, SEP 16 2024·9:18 AM EDT | UPDATED MON, SEP 16 2024·11:30 AM EDT



**Angelica Peebles**  
[@IN/ANGELICAPEEBLES/](#)  
[@ANGELICAPEEBLES](#)

SHARE [f](#) [X](#) [in](#) [✉](#)

## KEY POINTS

- Bristol Myers Squibb, AstraZeneca, Eli Lilly and other pharmaceutical companies have spent some \$10 billion on radiopharmaceutical acquisitions and partnerships over the past year.
- Drugmakers are trying to replicate the success Novartis has found with Pluvicto and Lutathera.
- Radiopharmaceuticals are currently available for some neuroendocrine tumors and prostate cancer. They could one day be used for numerous cancers.



[Prefer to Listen?](#)

NOW

UP NEXT

VIVA

# Options with Children

Inject a regular dose

Do an ultra-fast acquisition

Avoid anaesthesia

Cope with a non-compliant kid

Inject a low/ultralow dose

Do a longer scan

Avoid as much radiation burden as possible


European Journal of Nuclear Medicine and Molecular Imaging  
<https://doi.org/10.1007/s00259-022-05979-3>

IMAGE OF THE MONTH


Ultra-low dose infection imaging of a new long axial field-of-view PET/CT

N. D. van Rijsewijk<sup>1</sup> · B. van Leer<sup>1,2</sup> · O. V. Ivashchenko<sup>1</sup> · E. H. S. R. H. J. A. Slart<sup>1</sup> · W. Noordzij<sup>1</sup> · A. W. J. M. Glaudemans<sup>1</sup>

12 MBq FDG  
3min acq.




Morbus Hodgkin, 8y, 27kg, nodal, splenic and osseous manifestation





# Low-count Statistics

HCC  
SIRT 1 GBq 90Y-TheraSphere i.a.  
PET/CT 1d p.i. on Quadra



→ Therapy control dosimetry

European Journal of Nuclear Medicine and Molecular Imaging (2023) 50:1168–1182  
<https://doi.org/10.1007/s00259-022-06074-3>


ORIGINAL ARTICLE



## Phantom-based evaluation of yttrium-90 datasets using biograph vision quadra

Konstantinos G. Zeimpekis<sup>1</sup> · Lorenzo Mercolli<sup>1</sup> · Maurizio Conti<sup>2</sup> · Hasan Sari<sup>3</sup> · George Prenosil<sup>1</sup> · Kuangyu Shi<sup>1</sup> · Axel Rominger<sup>1</sup>

Received: 6 August 2022 / Accepted: 4 December 2022 / Published online: 12 December 2022  
© The Author(s) 2022



European Journal of Nuclear Medicine and Molecular Imaging  
<https://doi.org/10.1007/s00259-024-06650-9>

ORIGINAL ARTICLE



## <sup>90</sup>Y post-radioembolization clinical assessment with whole-body Biograph Vision Quadra PET/CT: image quality, tumor, liver and lung dosimetry

Konstantinos G. Zeimpekis<sup>1</sup> · Lorenzo Mercolli<sup>1</sup> · Maurizio Conti<sup>2</sup> · Hasan Sari<sup>3</sup> · Axel Rominger<sup>1</sup> · Hendrik Rathke<sup>1</sup>

Based on phantom and human studies 5 min acquisitions provide similar SNR compared to 30 min acq.



**→ Ultra-Low-Dose Imaging**

## Assessing Ultra-low Dose PET/CT and CT-less PET Using a Long Axial Field-of-view PET/CT System (ULD-PET)



The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. [Know the risks and potential benefits](#) of clinical studies and talk to your health care provider before participating. Read our [disclaimer](#) for details.

ClinicalTrials.gov Identifier: NCT05496920

[Recruitment Status](#) ⓘ: Recruiting

[First Posted](#) ⓘ: August 11, 2022

[Last Update Posted](#) ⓘ: August 19, 2022

See [Contacts and Locations](#)

**Recruitment finished**

**Sponsor:**

University Hospital Inselspital, Berne

**Information provided by (Responsible Party):**


University Hospital Inselspital, Berne

<https://clinicaltrials.gov/ct2/show/NCT05496920>

# Single centre, single-blinded cross-over non-inferiority trial tests the non-inferiority of a low-dose PET/CT compared to a reference standard – SAFOV FD-PET/CT

Aim: To demonstrate in a clinical setting the non-inferiority of low-dose using a clinically relevant endpoint by means of a robust, hypothesis testing prospective study

Framework: **comparison**



# Example



Vision  
Full dose (3 MBq/kg, 2 min/BP)



Quadra  
ULD (0.2 MBq/kg, 20 min)

SHORT COMMUNICATION

Open Access



## Ultra-low foetal radiation exposure in $^{18}\text{F}$ -FDG PET/CT imaging with a long axial field-of-view PET/CT system


Charlotte L. C. Smith<sup>1,2\*</sup>, Maqsood Yaqub<sup>1,2</sup>, Ruud H. H. Wellenberg<sup>1</sup>, Jelijn J. Knip<sup>2,3</sup>, Ronald Boellaard<sup>1,2</sup> and Gerben J. C. Zwezerijnen<sup>1,2</sup>

0.3 MBq/kg FDG

foetal radiation dose 0.11 and 0.44 mGy

CT: < 0.1-0.9 mGy

Total: < 1.5 mGy



**Fig. 1**  $^{18}\text{F}$ -FDG PET/CT image including both the mother and the foetus with (a) a Maximum Intensity Projection (MIP)  $^{18}\text{F}$ -FDG PET image and (b) a slice of the ultra-low-dose CT scan

.....  **Screening**

## ... in healthy volunteers

## Materials



- Four subjects received a single bolus administration of  $^{18}\text{F}$ -FDG (mean activity:  $7.92 \pm 0.98$  MBq, approx. 0.1 MBq/kg).
- PET emission data were acquired for 90 minutes starting from 60 min post injection using Biograph Vision Quadra (Siemens Healthineers) LAFOV PET system.
- Low-dose whole-body CT scans were performed with Care 4D, 100 kV and spectral shaping / tin filter.
  - CT-based  $\mu$ -maps were generated.
- LSO-TX data were acquired for 5 minutes using a special acquisition protocol with open energy and coincidence timing windows.
- PET images were reconstructed with CT- and LSO-TX-based  $\mu$ -maps using PSFTOF with 4 iterations and 5 subsets. Gaussian filter with 2 mm FWHM was applied.



# Development and evaluation of a CT-less reconstruction framework for long-axial FOV PET scanners using LSO background radiation

- High sensitivity of LAFOV PET scanners can be utilized to detect background LSO radiation (LSO-TX) from lutetium-based scintillators.
- In this work, we explore use of a deep-learning based method to generate CT-less attenuation maps from LSO-TX data

European Journal of Nuclear Medicine and Molecular Imaging (2022) 49:4490–4502  
<https://doi.org/10.1007/s00259-022-05909-3>


ORIGINAL ARTICLE




Quantitative evaluation of a deep learning-based framework to generate whole-body attenuation maps using LSO background radiation in long axial FOV PET scanners

Hasan Sari<sup>1,2</sup> · Mohammadreza Teimoorisichani<sup>2</sup> · Clemens Mingels<sup>2</sup> · Ian Alberts<sup>2</sup> · Vladimir Panin<sup>3</sup> · Deepak Bharkhada<sup>3</sup> · Song Xue<sup>2</sup> · George Prenosil<sup>2</sup> · Kuangyu Shi<sup>2</sup> · Maurizio Conti<sup>3</sup> · Axel Rominger<sup>2</sup>

Attenuation maps





Reconstructed PET images



## CASE 1

Injected Dose:  
9.0 MBq  
Patient Weight:  
75 kg


= 0.12 MBq/kg  
= 0.17 mSv



## CASE 2

Injected Dose:  
6.7 MBq  
Patient Weight:  
82 kg

= 0.08 MBq/kg  
= 0.12 mSv



Acq. duration: 90 min, 60 min. p.i.  
PSFTOF, 4i5s, 2 mm FWHM Gaussian filter, Matrix 440 x 440

Sari et al  
TBPET 2024

Injected Dose: 9.0 MBq  
Patient Weight: 75 kg  
Acq duration: 90 minutes  
CT-based AC





# Dual Tracer

# FDG chasing PSMA

150 MBq  
Ga-PSMA11  
1h p.i.

+ 40 MBq  
FDG  
1h later



2h15min for a theranostic  
assessment of PSMA-RLT



Ga-PSMA11

+ FDG

Alberts et al. EJNMMI 2022

# Dual PET based on triple coincidences

- Some non-standard PET isotopes produce spurious  $\gamma$  rays at the same time as the positron.
- The detection of the  $\gamma$  rays in coincidences with photons from the annihilation of the positron produce “triple coincidences”.
- Triple coincidences produced can be identified in the list mode from conventional scanners via:
  - Coincidences within the same time window sharing one of the crystals of interaction.
  - Identification of the energy characteristic of the additional  $\gamma$  rays.
- Some potential candidates for Dual PET:  $^{124}\text{I}$ ,  $^{52}\text{Mn}$ ,  $^{44}\text{Sc}$ ,  $^{82}\text{Rb}$ ,  $^{60}\text{Cu}$ ,  $^{86}\text{Y}$ ,  $^{68}\text{Ga}$




Improved Techniques for PET Imaging. Lopez-Montes, A. (2021). Thesis. <https://hdl.handle.net/20.500.14352/3369>

# Dynamic Imaging

# Multiparametric PET



SUV image  
static



Patlak Ki image  
[ $\mu\text{mol}/\text{min}/100\text{ml}$ ]  
(Slope)  
= metabolically  
trapped FDG





Patlak DV image  
[%]  
(Intercept)  
= non-metabolized/  
non-trapped FDG



# Multiparametric Imaging

IDIFs

Organ TACs



European Journal of Nuclear Medicine and Molecular Imaging (2023) 50:257–265  
<https://doi.org/10.1007/s00259-022-05983-7>

ORIGINAL ARTICLE




**Feasibility of using abbreviated scan protocols with population-based input functions for accurate kinetic modeling of [<sup>18</sup>F]-FDG datasets from a long axial FOV PET scanner**

Hasan Sari<sup>1,2</sup> · Lars Eriksson<sup>3,4</sup> · Clemens Mingels<sup>2</sup> · Ian Alberts<sup>2</sup> · Michael E. Casey<sup>3</sup> · Ali Afshar-Oromieh<sup>2</sup> · Maurizio Conti<sup>3</sup> · Paul Cumming<sup>2,5</sup> · Kuangyu Shi<sup>2</sup> · Axel Rominger<sup>2</sup>

Received: 17 June 2022 / Accepted: 20 September 2022 / Published online: 4 October 2022  
© The Author(s) 2022



Available for  
clinical routine



Sari et al. (2022) EJNMMI

We demonstrate the feasibility of performing accurate [<sup>18</sup>F]-FDG Patlak analysis using sPBIFs with only 15-20 min of PET data from a LAFOV PET scanner.

ACTIVE, NOT RECRUITING ⓘ

## Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007

ClinicalTrials.gov ID ⓘ NCT05079828

Sponsor ⓘ Insel Gruppe AG, University Hospital Bern

Information provided by ⓘ Insel Gruppe AG, University Hospital Bern (Responsible Party)

Last Update Posted ⓘ 2024-06-07

Study Start (Actual) ⓘ

2022-07-07

Primary Completion (Actual) ⓘ

2024-05-01

Study Completion (Estimated) ⓘ

2024-11-01

Enrollment (Actual) ⓘ

100

Study Type ⓘ

Interventional

Phase ⓘ

Not Applicable


# <sup>18</sup>F-PSMA-1007



# <sup>68</sup>Ga-PSMA-11



**Data acq.  
finished**



79 year old male, 55 kg

Injected doses:

18F-PSMA-1007: 270 MBq

Ga68-PSMA-11: 168 MBq

2 x 60 min long dynamic scans

PET data modelled using 2TC model




Sari H et al, TBPET 2024

# Dynamic $^{18}\text{F}$ -FET analysis with Biograph Vision Quadra

1 min


10 min

40 min



**Patlak DV**

**Patlak Ki**



# Total-Body PET in Cardiovascular Disease

European Journal of Nuclear Medicine and Molecular Imaging  
<https://doi.org/10.1007/s00259-023-06242-z>

IMAGE OF THE MONTH




## First-time rest-stress dynamic whole-body $^{82}\text{Rb}$ -PET imaging using a long axial field-of-view PET/CT scanner

Federico Caobelli<sup>1</sup>  · Sigrid Seibel<sup>1</sup> · Korbinian Krieger<sup>1</sup> · Carola Bregenzer<sup>1</sup> · Marco Viscione<sup>1</sup> · Angela Filipa Silva Mendes<sup>1</sup> · Hasan Sari<sup>1,2</sup> · Lorenzo Mercolli<sup>1</sup> · Ali Afshar-Oromieh<sup>1</sup> · Axel Rominger<sup>1</sup>

Received: 24 February 2023 / Accepted: 19 April 2023  
© The Author(s) 2023

# Dynamic images




0-30 sec

30-60 sec

60-120 sec

2-7 min




European Journal of Nuclear Medicine and Molecular Imaging  
<https://doi.org/10.1007/s00259-023-06292-3>

EDITORIAL

## The future of atherosclerosis assessment: dynamic and quantitative whole-body PET cardiovascular imaging

Federico Caobelli<sup>1</sup> · Christoph Gräni<sup>2</sup> · Axel Rominger<sup>1</sup>



SHORT COMMUNICATION




**Table 1** Personal details of the three subjects and administered activity for the rest and stress examinations


| Subject | Gender | Age [y] | Weight [kg] | Height [m] | Activity rest [MBq] | Activity stress [MBq] |
|---------|--------|---------|-------------|------------|---------------------|-----------------------|
| P1      | F      | 57      | 57          | 1.65       | 407.00              | 407.03                |
| P2      | M      | 29      | 88          | 1.96       | 404.59              | 409.19                |
| P3      | M      | 40      | 84          | 1.72       | 398.43              | 401.73                |

## Internal dosimetry study of [<sup>82</sup>Rb]Cl using a long axial field-of-view PET/CT

Lorenzo Mercolli<sup>1</sup> · Carola Bregenzner<sup>1</sup> · Markus Diemling<sup>2</sup> · Clemens Mingels<sup>1</sup> · Axel Rominger<sup>1</sup> · Hasan Sari<sup>3</sup> · Sigrid Seibel<sup>1</sup> · Antti Sohlberg<sup>2,4</sup> · Marco Viscione<sup>1</sup> · Federico Caobelli<sup>1</sup>



**Fig. 1** Maximum intensity projection (MIP) of the three subjects at rest. The images depict the full scan integration





Total body effective dose  
0.50 – 0.76 µSv/MBq

# Positronium Lifetime Imaging – Histoimage of triplet events

Histoimage [68Ga]Ga-DOTA-TOC




Histoimage [82Rb]Cl



«Weave» program / OPUS LAP

# Patient Flow



Claustrophobia  
(not all)  
Non-oncological  
indications



# Trend over the last four years in our center

Conventional PET


30%

LAFOV PET

70%

Acq  
time  
1 min

Acq  
time  
2 min



2014



2018




2020

- Non- oncological indications ↑
- Variety of radiotracers ↑
- PET in theranostics ↑
- Radiation burden ↓
- Acquisition time →
- Dual tracer studies ↑
- Multiparametric imaging ↑
- Total body information ↑
- PET data in healthy ↑

**2024 - 2030**



LAFOV Systems  
>100 cm



SAFOV systems with  
ultra-fast TOF

LAFOV systems

## Key Challenges

- To optimally exploit the flexibility of the systems
- LAFOV systems are packed → stratification of patients to different systems, everybody wants the best scanner → raising demand
- Reorganization of the tech staff team, reorganization of scheduling system
- Data storage and IT environment
- Dedicate enough research time on the system

# Conclusion and Outlook

- Clear advantages compared to SAFOV scanners
  - clinically
  - scientifically
- A lot of clinical benefits derive from the high sensitivity
- Approval of new radiopharmaceuticals are facilitated by LAFOV scanners
- In future more radiopharmaceuticals will be available and administered to patients with lower doses
- Radiation-sensitive patient cohorts will be increasing in numbers



# Conclusion after >10'000 Quadra Scans in Bern

- Mature and robust systems
- Clear advantages compared to SAFOV scanners
  - clinically
  - scientifically
- All-in-one devices suitable for very many purposes



Alberts et al. *Cancer Imaging* (2023) 23:28  
<https://doi.org/10.1186/s40644-023-00540-3>


Cancer Imaging

REVIEW

Open Access

Long-axial field-of-view PET/CT: perspectives and review of a revolutionary development in nuclear medicine based on clinical experience in over 7000 patients

Ian Alberts<sup>1</sup>, Hasan Sari<sup>1,2</sup>, Clemens Mingels<sup>1</sup>, Ali Afshar-Oromieh<sup>1</sup>, Thomas Pyka<sup>1</sup>, Kuangyu Shi<sup>1</sup> and Axel Rominger<sup>1</sup> 



**Thank you very much for your attention!**